Terns Pharma - TERN Net Assets per Single Share

Terns Pharmaceuticals (TERN) is currently conducting active trials for its pipeline of breakthrough obesity and liver pathology drugs, laying the foundation for long-term commercial success. Operational efficiency is supported by streamlined clinical trial logistics featuring strict temperature control. The quotes provided below, where the indicator is 9.01, complement the profile of a company developing affordable small molecules for the therapy of metabolic disorders.

Terns Pharma (TERN): Share Book Value from 07/04/2022 to 05/16/2026

ternspharma.com - analytical breakdowns and key metrics (TERN)

- price and consensus price forecast:

Price Chart Terns Pharmaceuticals Inc|TERN - Fair Value Consensus

- market capitalization data:

Market Value Terns Pharmaceuticals, Inc.|TERN - Business Value

- book capitalization data:

Net Assets per Single Share Terns Pharmaceuticals|TERN - Net Asset Value|Market Capitalization to Book Value Ratio ternspharma.com|TERN - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Terns Pharmaceuticals|TERN - Long-Term Debt to Capital|Short-Term Debt to Equity Terns Pharmaceuticals, Inc.|TERN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Terns Pharmaceuticals, Inc.

Fundamental company valuation:Terns Pharmaceuticals Inc - TERN

Manufactured products of Terns Pharmaceuticals, Inc.

Searching for fundamentally resilient assets requires an analysis of a business's intrinsic value. Book value per share measures the portion of equity attributable to a single security after deducting all liabilities. For Terns Pharmaceuticals (TERN), this metric reflects the volume of resources allocated to the development of oral gastrointestinal drugs. Investments in clinical trials establish the foundation for a future patent monopoly. Evaluate the book value per common share trend to monitor capitalization without market noise.

Competitors of Terns Pharmaceuticals (TERN)

Net Assets per Single Share Phathom Corp (PHAT)|IRWD: Accounting Value of a Share|Net Assets per Single Share curanexpharma.com|IMRN (Immuron) - Equity per Share|Net Assets per Single Share Evoke Pharma EVOK|Share Book Value Entero|RedHill Biopharma (RDHL) - Book Value per Share|Accounting Value of a Share Palisade Bio Inc. (PALI)|Book Value per Share JAGX (Jaguar Health, Inc.)|bioratherapeutics.com - Book Value per Share|Net Assets per Single Share Morphic (MORF)